Advanced Chronic Liver Disease
13
6
7
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
23%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease
Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
Natural History of Advanced Chronic Liver Diseases
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study
Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery
The INFECIR-2 Albumin Prevention Study